CTOR · Citius Oncology Inc
United States · RS rating 11 · As of 2026-11-03
| Price | 0.55 USD |
|---|---|
| 1-day change | -7.4% |
| RS rating (overall / 1M / 3M / 12M) | 11 / 8 / 21 / 13 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 17 / 4 / 17 |
| Industry group (rank) | Medical-Generic Drugs (136) |
| EPS growth Q/Q | -350.0% |
| Sales growth Q/Q | -57.7% |
| Distance from 52-week high | +67.1% |
| Market cap (USD) | $86.3M |